BR9206237A - Uso de derivados de tetrahidrocarbazole como receptores agonistas 5-HT1. - Google Patents

Uso de derivados de tetrahidrocarbazole como receptores agonistas 5-HT1.

Info

Publication number
BR9206237A
BR9206237A BR9206237A BR9206237A BR9206237A BR 9206237 A BR9206237 A BR 9206237A BR 9206237 A BR9206237 A BR 9206237A BR 9206237 A BR9206237 A BR 9206237A BR 9206237 A BR9206237 A BR 9206237A
Authority
BR
Brazil
Prior art keywords
tetrahydrocarbazole derivatives
agonist receptors
agonist
receptors
tetrahydrocarbazole
Prior art date
Application number
BR9206237A
Other languages
English (en)
Portuguese (pt)
Inventor
Francis David King
Laramie Mary Gaster
Alberto Julio Kaumann
Rodney Christopher Young
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10697363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9206237(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of BR9206237A publication Critical patent/BR9206237A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9206237A 1991-06-26 1992-06-17 Uso de derivados de tetrahidrocarbazole como receptores agonistas 5-HT1. BR9206237A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919113802A GB9113802D0 (en) 1991-06-26 1991-06-26 Medicaments
US08/167,846 US5464864A (en) 1991-06-26 1992-06-17 Use of tetrahydrocarbazone derivatives as 5HT1 receptor agonists
PCT/GB1992/001082 WO1993000086A1 (en) 1991-06-26 1992-06-17 Use of tetrahydrocarbazone derivatives as 5ht1 receptor agonists

Publications (1)

Publication Number Publication Date
BR9206237A true BR9206237A (pt) 1995-04-11

Family

ID=10697363

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9206237A BR9206237A (pt) 1991-06-26 1992-06-17 Uso de derivados de tetrahidrocarbazole como receptores agonistas 5-HT1.
BR1100460-6A BR1100460A (pt) 1991-06-26 1997-05-06 Uso de derivados de tetrahidrocarbazole como receptores agonistas 5-ht1

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR1100460-6A BR1100460A (pt) 1991-06-26 1997-05-06 Uso de derivados de tetrahidrocarbazole como receptores agonistas 5-ht1

Country Status (34)

Country Link
US (2) US5464864A (enExample)
EP (1) EP0591280B1 (enExample)
JP (1) JP3261502B2 (enExample)
KR (1) KR100251571B1 (enExample)
CN (1) CN1034072C (enExample)
AP (1) AP344A (enExample)
AT (1) ATE170746T1 (enExample)
BR (2) BR9206237A (enExample)
CA (1) CA2113726C (enExample)
CZ (3) CZ150596A3 (enExample)
DE (2) DE69226953T2 (enExample)
DK (1) DK0591280T3 (enExample)
FI (1) FI103967B1 (enExample)
GB (1) GB9113802D0 (enExample)
HU (1) HU218907B (enExample)
IE (1) IE922062A1 (enExample)
IL (4) IL117104A (enExample)
LU (1) LU90939I2 (enExample)
MA (1) MA22563A1 (enExample)
MX (1) MX9203444A (enExample)
NL (1) NL300103I2 (enExample)
NO (2) NO304774B1 (enExample)
NZ (1) NZ243288A (enExample)
PL (3) PL169410B1 (enExample)
PT (1) PT100620B (enExample)
RU (1) RU2137474C1 (enExample)
SA (1) SA92130141B1 (enExample)
SG (1) SG47877A1 (enExample)
SI (1) SI9200125B (enExample)
SK (3) SK280907B6 (enExample)
TW (1) TW214544B (enExample)
UA (1) UA41254C2 (enExample)
WO (1) WO1993000086A1 (enExample)
ZA (1) ZA924658B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
US5616603A (en) * 1995-05-26 1997-04-01 Smithkline Beecham Plc Enantiomers of carbazole derivatives as 5-HT1 -like agonists
GB9226530D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
GB9226566D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
US5618948A (en) * 1995-05-26 1997-04-08 Smithkline Beecham P.L.C. Process for preparing an enantiomer of a carbazole derivative
CA2179678A1 (en) * 1995-06-23 1996-12-24 Michael Edward Flaugh 6-substituted-1,2,3,4-tetrahydro-9h-carbazoles and 7-substituted-10h-cyclohepta¬7,6-b| indoles
US5917054A (en) * 1995-07-18 1999-06-29 Smithkline Beecham P.L.C. Process for preparing enantiomers of carbazole derivatives as 5-HT1 -like agonists
US5708187A (en) * 1996-06-27 1998-01-13 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
GB9723061D0 (en) * 1997-10-31 1998-01-07 Vanguard Medica Ltd Medicaments
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
GB9808069D0 (en) 1998-04-16 1998-06-17 Vanguard Medica Ltd Novel processes
GB9817911D0 (en) * 1998-08-17 1998-10-14 Vanguard Medica Ltd New use
US20030198669A1 (en) * 2001-07-05 2003-10-23 R.T. Alamo Ventures I, Llc Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
US20030017175A1 (en) * 2001-07-05 2003-01-23 R.T. Alamo Ventures I, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine
US6685951B2 (en) 2001-07-05 2004-02-03 R. T. Alamo Ventures I, Inc. Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
ES2291503T3 (es) * 2001-09-28 2008-03-01 F. Hoffmann-La Roche Ag Formas pseudopolimorficas de carvedilol.
JP4455992B2 (ja) 2002-06-21 2010-04-21 スベン ライフ サイエンシズ リミティド 治療薬剤として有用なセロトニン受容体親和性を有するアリールアルキル・インドール、その製造方法、並びにそれらを含む医薬組成物
NZ537770A (en) 2002-06-21 2007-03-30 Suven Life Sciences Ltd Tetracyclic arylsulfonyl indoles having serotonin receptor affinity
EA009193B1 (ru) 2002-11-28 2007-12-28 Сувен Лайф Сайенсиз Лимитед N-арилсульфонил-3-аминоалкоксииндолы
DK1581492T3 (da) 2002-11-28 2008-11-10 Suven Life Sciences Ltd N-arylsulfonyl-3-substituerede indoler med serotoninreceptoraffinitet, fremgangsmåde til fremstilling heraf og en farmaceutisk sammensætning indeholdende disse
EA009367B1 (ru) 2002-12-18 2007-12-28 Сувен Лайф Сайенсиз Лимитед ПРОИЗВОДНЫЕ 5-ТИА-5-ДИОКСО-4b-АЗАИНДЕНО[2,1-a]ИНДЕНА, ОБЛАДАЮЩИЕ АФФИННОСТЬЮ К РЕЦЕПТОРУ СЕРОТОНИНА
RU2430088C2 (ru) * 2004-07-14 2011-09-27 Центарис Гмбх Производные тетрагидрокарбазола и фармацевтическая композиция на их основе
US7601856B2 (en) 2006-07-27 2009-10-13 Wyeth Benzofurans as potassium ion channel modulators
KR101411820B1 (ko) * 2006-08-07 2014-06-24 액테리온 파마슈티칼 리미티드 (3-아미노-1,2,3,4-테트라하이드로-9ｈ-카르바졸-9-일)-아세트산 유도체
EP2813144A1 (en) 2006-10-09 2014-12-17 Charleston Laboratories, Inc. Analgesic compositions comprising an antihistamine
US8148377B2 (en) 2007-02-11 2012-04-03 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US20090069399A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched frovatriptan
JP5714910B2 (ja) 2008-01-09 2015-05-07 チャールストン ラボラトリーズ，インコーポレイテッド 薬学的組成物
WO2010073253A1 (en) * 2008-12-22 2010-07-01 Natco Pharma Limited Method for preparing an optically active frovatriptan
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
US10098674B2 (en) 2009-10-22 2018-10-16 Nuvasive, Inc. System and method for posterior cervical fusion
US9204906B2 (en) 2009-10-22 2015-12-08 Nuvasive, Inc. Posterior cervical fusion system and techniques
EP3628325A1 (en) 2011-07-22 2020-04-01 The University of Chicago Treatments for migraine and related disorders
HK1216250A1 (zh) 2012-12-21 2016-10-28 Map Pharmaceuticals, Inc. 8'-羟基-二氢麦角胺化合物及组合物
EP2816030A1 (en) 2013-06-20 2014-12-24 Duke Chem, S. A. Process for the preparation of frovatriptan and its enantiomer
GB201312768D0 (en) 2013-07-17 2013-08-28 Ge Healthcare Ltd Work-up procedure
JP2019507181A (ja) 2016-03-04 2019-03-14 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
EP3766483A1 (en) 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Orodispersible powder composition comprising a triptan
WO2025038666A2 (en) * 2023-08-13 2025-02-20 GATC Health Corp Compounds and methods for treating addiction
CN119499195A (zh) * 2024-11-26 2025-02-25 青岛国信制药有限公司 一种快速吸收琥珀酸呋罗曲坦片及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642816A (en) * 1967-08-10 1972-02-15 Sterling Drug Inc 3-acetamido-1 2 3 4-tetrahydrocarbazole
US4062864A (en) * 1968-01-24 1977-12-13 Sterling Drug Inc. 3-Hydroxy carbazole derivatives
US3959309A (en) * 1968-01-24 1976-05-25 Sterling Drug Inc. 3-Amido-1,2,3,4-tetrahydrocarbazoles
US3592824A (en) * 1970-03-12 1971-07-13 Miles Lab 3-substituted amino-1,2,3,4-tetrahydrocarbazoles
BE787537A (fr) * 1971-08-16 1973-02-14 Sterling Drug Inc Tetrahydrocarbazoles
US4172834A (en) 1971-08-16 1979-10-30 Sterling Drug Inc. 3-Amino-tetrahydrocarbazoles
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US4257952A (en) * 1977-06-06 1981-03-24 Sterling Drug Inc. 3-Amino-tetrahydrocarbazoles
US4254134A (en) * 1978-03-17 1981-03-03 Endo Laboratories, Inc. Antidepressant 2-amino- and -2-(substituted amino)-cis-hexahydro-carbazoles
EP0115607A1 (de) * 1983-01-04 1984-08-15 MERCK PATENT GmbH Tetrahydrocarbazolderivate

Also Published As

Publication number Publication date
ZA924658B (en) 1993-12-24
CZ150696A3 (en) 1997-06-11
IL102322A (en) 1997-09-30
AU1977592A (en) 1993-01-25
SK280906B6 (sk) 2000-09-12
EP0591280B1 (en) 1998-09-09
NO934800L (no) 1993-12-23
AU652842B2 (en) 1994-09-08
CA2113726C (en) 2008-02-19
SI9200125A (en) 1992-12-31
SI9200125B (en) 2001-12-31
WO1993000086A1 (en) 1993-01-07
GB9113802D0 (en) 1991-08-14
EP0591280A1 (en) 1994-04-13
SG47877A1 (en) 1998-04-17
SK131993A3 (en) 1994-06-08
ATE170746T1 (de) 1998-09-15
IL117105A (en) 1998-01-04
IL102322A0 (en) 1993-01-14
FI935842A7 (fi) 1993-12-23
JPH06508827A (ja) 1994-10-06
CZ282327B6 (cs) 1997-06-11
LU90939I2 (fr) 2002-09-24
IE922062A1 (en) 1992-12-30
BR1100460A (pt) 2000-07-18
PL171034B1 (en) 1997-02-28
HUT68961A (en) 1995-08-28
CZ282083B6 (cs) 1997-05-14
SK280905B6 (sk) 2000-09-12
CZ282061B6 (cs) 1997-05-14
AP9200403A0 (en) 1992-07-31
US5464864A (en) 1995-11-07
NO2005011I1 (no) 2005-05-18
PT100620A (pt) 1993-09-30
NL300103I1 (nl) 2002-12-02
IL117104A0 (en) 1996-06-18
KR100251571B1 (ko) 2000-07-01
CN1034072C (zh) 1997-02-19
CZ150596A3 (en) 1997-05-14
DE10299042I2 (de) 2005-02-03
CN1069726A (zh) 1993-03-10
DE10299042I1 (de) 2003-02-20
SK280907B6 (sk) 2000-09-12
NL300103I2 (nl) 2003-02-03
DE69226953D1 (de) 1998-10-15
CA2113726A1 (en) 1993-01-07
DE69226953T2 (de) 1999-05-12
IL117104A (en) 1997-09-30
SA92130141B1 (ar) 2005-12-18
RU2137474C1 (ru) 1999-09-20
PL169410B1 (pl) 1996-07-31
FI103967B (fi) 1999-10-29
JP3261502B2 (ja) 2002-03-04
CZ286193A3 (en) 1994-07-13
HU218907B (hu) 2000-12-28
HK1014669A1 (en) 1999-09-30
UA41254C2 (uk) 2001-09-17
US5637611A (en) 1997-06-10
MX9203444A (es) 1993-12-01
NZ243288A (en) 1994-09-27
NO2005011I2 (no) 2008-02-11
AP344A (en) 1994-07-05
DK0591280T3 (da) 1999-02-15
NO934800D0 (no) 1993-12-23
MA22563A1 (fr) 1992-12-31
NO304774B1 (no) 1999-02-15
PL169392B1 (pl) 1996-07-31
TW214544B (enExample) 1993-10-11
FI935842A0 (fi) 1993-12-23
FI103967B1 (fi) 1999-10-29
PT100620B (pt) 1999-01-29
IL117105A0 (en) 1996-06-18

Similar Documents

Publication Publication Date Title
BR9206237A (pt) Uso de derivados de tetrahidrocarbazole como receptores agonistas 5-HT1.
FI943247L (fi) Piperatsiinijohdannaisia 5-HT-reseptoriantagonisteina
FI973205A7 (fi) Indolijohdannaisia 5-HT-reseptoriantagonisteina
KR950700906A (ko) 5-ht1 작동약으로서의 인돌 유도체(indole derivatives as 5-ht1 agonists)
FI942187A7 (fi) Asyklisiä etyleenidiamiinijohdannaisia aine P-reseptoriantagonisteina
FI944729L (fi) Perhydroisoindolijohdannaiset substanssi P:n antagonisteina
DK0630376T3 (da) Kondenserede indolderivater som 5-HT4-receptorantagonister
DK0901470T3 (da) Indolderivater egnede som endothelinreceptorantagonister
DK0856001T3 (da) Pyrimidinderivater som 5-HT2C-receptor-antagonister
DE69232003D1 (de) Benzanilidderivate als 5-HT1D-Antagonisten
FI941178L (fi) 5-HT4-reseptoriantagonisteja
FI961628A0 (fi) Indolijohdannaisia NMDA-antagonisteina
FI962969L (fi) Indolijohdannaisia 5-HT1:n agonisteina
BR9406435A (pt) Utilização de derivados de indol como antagonistas de 5HT1
FI944727L (fi) Indolijohdannaisia 5-HT1:n kaltaisina agonisteina
PT1200400E (pt) Derivados de pirrolidino-2,3,4-trion-3-oxina substituidas com eficacia como antagonistas do receptor nmda
DE69703242D1 (de) Indolin-derivate verwendbar als 5-ht-2c rezeptor-antagonisten
FI951798A7 (fi) Bentsofuraanijohdannaiset 5-HT1-kaltaisina reseptoriantagonisteina
DE69717449D1 (de) Indolin-derivate verwendbar als 5-ht-2c rezeptor-antagonisten
DE69004827D1 (de) Alpha-adrenergene Rezeptor-Antagonisten.
IT1296975B1 (it) Derivati chinolinici procedimento per la loro preparazione e uso come antagonisti del recettore nk3
IT1295356B1 (it) Derivati chinolinici, procedimento per la loro preparazione e uso come antagonisti del recettore nk3
IT9040011A0 (it) Fresa per uso dentale.

Legal Events

Date Code Title Description
EE Request for examination
FA Application withdrawn